Novel vaccines to human rabies.

Area of Science:

• Public Health
• Infectious Diseases
• Vaccinology

Background:

• Rabies is a fatal zoonotic disease causing an estimated 55,000 deaths annually, predominantly in children in Southeast Asia and Africa.
• Current rabies prevention requires multiple vaccine doses and, in severe cases, rabies immunoglobulin (RIG), which are costly and inaccessible.
• Lack of knowledge, access to post-exposure prophylaxis (PEP), and adherence to vaccination schedules contribute to high rabies incidence.

Purpose of the Study:

• To review the pipeline of novel rabies vaccines in pre-clinical development.
• To identify promising candidates for replacing current rabies vaccines and improving PEP strategies.
• To address the need for inexpensive, safe, and sustained-protection rabies vaccines, especially for children in high-incidence regions.

Main Methods:

• Review of pre-clinical data for new rabies virus vaccines.
• Analysis of potential novel vaccination and post-exposure prophylaxis (PEP) regimens.
• Evaluation of vaccine characteristics such as immunogenicity, cost, safety, and required dosage.

Main Results:

• The review details various rabies vaccine candidates in pre-clinical stages.
• Emerging vaccines show potential for increased immunogenicity and reduced cost compared to current options.
• Novel PEP regimens aim to decrease reliance on scarce and expensive rabies immunoglobulin (RIG) and reduce vaccine doses.

Conclusions:

• Development of new, cost-effective rabies vaccines and simplified PEP regimens is crucial for reducing global rabies mortality.
• Single-dose, sustained-protection vaccines are a key goal for widespread immunization, particularly in vulnerable populations.
• The reviewed pre-clinical pipeline offers hope for improved rabies control strategies.